Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that CEO Todd C. Brady, M.D., Ph.D. will discuss reproxalap as a novel treatment for dry eye disease at the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase on March 11, 2021, from 1:00 p.m. to 4:00 p.m. ET. The virtual event features market overviews, company presentations, and expert panel discussions on the dry eye disease market. Registration is free. Aldeyra is focused on developing therapies for immune-mediated diseases and is conducting Phase 3 trials for reproxalap and other investigational compounds.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of reproxalap as a novel, rapid-onset first-line treatment for dry eye disease as part of the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase, which will take place virtually on Thursday, March 11, 2021 from 1:00 p.m. to 4:00 p.m. ET.

The event will include a market overview and company presentations as well as panel discussions featuring experts who will provide industry and clinical perspectives on the dry eye disease market.

Registration is complimentary. To register, click here: https://bit.ly/3chgZJh

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005189/en/

FAQ

What is reproxalap and its significance for dry eye disease?

Reproxalap is a novel, rapid-onset treatment for dry eye disease, currently being discussed by Aldeyra Therapeutics' CEO at the Ophthalmology Innovation Summit.

When is the Ophthalmology Innovation Summit showcasing dry eye disease innovations?

The summit will take place virtually on March 11, 2021, from 1:00 p.m. to 4:00 p.m. ET.

How can I register for the Dry Eye Disease Innovation Showcase?

Registration for the event is complimentary and can be completed through the provided link in the press release.

What clinical trials is Aldeyra Therapeutics conducting?

Aldeyra is conducting Phase 3 clinical trials for reproxalap in dry eye disease and allergic conjunctivitis, among other investigational compounds.

What does Aldeyra Therapeutics focus on?

Aldeyra is a biotechnology company focused on developing novel therapies for patients with immune-mediated diseases.